Developer docs
API playgroundTry for free, no card

Search company profiles

Proveca

Full company profile

uuid0003znt

Namestring
Proveca
Legal namestring
Proveca Ltd
Websiteurl
proveca.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Proveca is a UK-based specialty pharmaceutical company founded in 2010 by Simon Bryson and Helen Shaw, exclusively focused on developing and licensing age-appropriate medicines for children. The company addresses the systemic problem that approximately half of medicines administered to children are in the wrong format or unlicensed for paediatric use, leading to safety and adherence risks. Proveca targets two therapeutic areas — neurology (chronic neurological disorders including cerebral palsy and epilepsy-related sialorrhoea) and cardiology (paediatric heart failure, hypertension, and oedema) — where approximately 80% of children with heart failure currently receive off-label adult medications. The company has contributed to 5 of the 10 PUMAs ever granted globally.

The core technology centres on proprietary orodispersible tablet formulations designed specifically for paediatric administration, including 2mm mini-tablets (Aqumeldi) and score-line tablets enabling accurate 2.5mg dosing (Bopediat). Three core products are Sialanar® (glycopyrronium bromide) for severe sialorrhea in children with chronic neurological disorders, Aqumeldi® (enalapril maleate) for paediatric heart failure, and Bopediat® (furosemide) pending European Commission approval. The pipeline includes Captopril, additional Enalapril and Furosemide protocols.

The business model is licensing-based commercialisation through the EMA PUMA pathway. Proveca generates revenue from product sales across direct sales channels in the EU and UK, plus distribution partnerships internationally (Tamro/Oriola for Nordics, Eurocept for Netherlands, BCWorld Healthcare for South Korea, and regional distributors in Eastern Europe and Latin America). Customer segments are paediatric healthcare providers (hospitals, paediatricians, neurologists, cardiologists), with end beneficiaries being children from birth to under 18 years. The company is venture capital-backed by AlbionVC and Catapult Ventures, operates through wholly-owned subsidiaries in the UK, Ireland, Germany, Italy, and France, and is pursuing US market entry via an FDA NDA for Aqumeldi submitted in March 2026.

Short descriptiontext

Proveca is a UK-based specialty pharmaceutical company founded in 2010 that develops and licenses age-appropriate medicines for children, focusing on paediatric neurology and cardiology through the EMA PUMA regulatory pathway across Europe and select international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersManchester, United Kingdom
HQ citystring
Manchester
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pediatric pharmaceuticals, age-appropriate formulations, orodispersible tablets, paediatric neurology medicines, paediatric cardiology medicines
Industry2 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAJADAI
Regulatory Affairs, Labeling & Advertising/Promotion Compliance
Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pediatric Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product sales - Sialanar
TypeLicensing Royalties
Description

Proveca generates revenue from commercialising licensed paediatric medicines. Sialanar® (glycopyrronium bromide) is marketed for neurological conditions including chronic drooling in children with neurological disorders.

2Product sales - Aqumeldi
TypeLicensing Royalties
Description

Aqumeldi® (enalapril maleate) is commercialised for paediatric heart failure in Europe and UK, with NDA submitted to FDA for US market expansion.

3Product sales - Bopediat
TypeLicensing Royalties
Description

Bopediat® (furosemide) orodispersible tablets received positive EMA opinion for PUMA, pending European Commission approval for treatment of oedema and hypertension in children.

proveca.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Bopediat®
Description

Furosemide orodispersible tablets for treatment of oedema and hypertension in children from birth to less than 18 years

proveca.com
+2 more records
Core offering1 text field

Proveca is a global pharmaceutical company that develops and licenses age-appropriate medicines for children in neurology and cardiology therapy areas. The company identifies off-patent medicines with unmet paediatric healthcare needs and obtains Paediatric Use Marketing Authorisations (PUMA) and other marketing authorisations to bring licensed paediatric formulations such as Sialanar® (glycopyrronium bromide), Aqumeldi® (enalapril maleate), and Bopediat® (furosemide) to market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 80% of children with heart failure currently receive off-label adult medications
+2 more records
Product overview1 text field

Proveca is a pharmaceutical company specialising in the development and licensing of medicines for children. The company focuses on identifying off-patent medicines with unmet priority healthcare needs in the paediatric market, obtaining paediatric licences through the PUMA (Paediatric Use Marketing Authorisation) pathway and national marketing authorisations. Current approved products include Sialanar® (glycopyrronium bromide) for neurological conditions causing chronic drooling/sialorrhea, and Aqumeldi® (enalapril maleate) for cardiology conditions. Bopediat® (furosemide) is pending European Commission approval. The product portfolio spans neurology and cardiology therapy areas, with medicines designed in age-appropriate formats such as orodispersible tablets.

Product and service3 records
1Sialanar®
CategoryPaediatric neurology medicine
Description

Glycopyrronium bromide 400mcg/ml oral solution indicated for symptomatic treatment of severe sialorrhea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Licensed via PUMA and launched across multiple European markets, South Korea, and South America.

2Aqumeldi®
CategoryPaediatric cardiology medicine
Description

Enalapril maleate orodispersible mini tablet (0.25mg and 1mg) indicated for treatment of heart failure in children from birth to less than 18 years, and for treatment of hypertension. Licensed for paediatric heart failure in Europe and UK, with NDA submitted to FDA for US market expansion.

3Bopediat®
CategoryPaediatric cardiology medicine
Description

Furosemide 5mg orodispersible tablet with functional score line enabling accurate 2.5mg doses. Indicated in children from birth to less than 18 years for treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease. Awaiting European Commission approval.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1BCWorld Healthcare
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-03-01
Description

In March 2024, Proveca entered into a partnership agreement with BCWorld Healthcare, granting exclusive rights for licensing and distribution of Sialanar® in South Korea. BCWorld submitted NDA in October 2024 and received marketing authorisation from MFDS in August 2025. The product launched in South Korea in March 2026 for treatment of severe sialorrhea in children aged 3 years and older with chronic neurological disorders.

proveca.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2022-11-29
Description

Proveca partnered with Aston University to support final research projects for MSc Pharmaceutical Sciences, Drug Delivery and MPharm students. The partnership includes PhD sponsorship, research supervision, workshops on drug formulation challenges, and student project support. Joint work explores development of drug formulations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-05
Description

Collaboration between Alder Hey Children's Hospital and Proveca Ltd to improve children's medicines. The partnership aims to provide the best pharmaceutical treatments for children by identifying existing gaps and developing new products specifically for children and young people. Alder Hey brings expertise in paediatric healthcare and their NIHR-funded Clinical Research Facility.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Tamro AB manages distribution of Proveca medicines to Norway, Sweden, Denmark, and Iceland, supplying these countries via local wholesalers.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Oriola AB is responsible for Proveca Pharma Ltd's regulatory, quality, and pharmacovigilance obligations in the Nordic region.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Eurocept Pharmaceuticals handles adverse event reporting and product distribution for Sialanar® and Aqumeldi® products in the Netherlands.

Strategic tierCoreTypeOthers
Description

Proveca works with EMA for regulatory approvals through the Paediatric Use Marketing Authorisation (PUMA) pathway. EMA CHMP adopted positive opinion for Bopediat® in March 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish Orphan Biovitrum is a European specialty pharmaceutical company focused on rare diseases and specialty medicines, including paediatric indications. Sobi's commercial model of licensing, developing, and distributing niche specialty medicines across global markets closely parallels Proveca's paediatric pharmaceutical strategy, though Sobi operates at significantly larger scale.

TypeBroad incumbent
Description

Jazz Pharmaceuticals acquired GW Pharmaceuticals, which developed cannabinoid-based paediatric epilepsy treatments, demonstrating a similar specialty pharma model of developing differentiated paediatric formulations for neurological conditions. Jazz represents a broader incumbent player with paediatric neurology exposure and significant commercial scale.

TypeBroad incumbent
Description

BioMarin is a specialty biopharmaceutical company focused on rare diseases, with several paediatric products across multiple therapeutic areas including neurology and cardiology. BioMarin's paediatric rare disease franchise, combined with global commercial infrastructure, makes it a comparable incumbent peer in paediatric specialty pharma, though at substantially larger scale.

TypeEmerging player
Description

Orchard Therapeutics is a biotechnology company developing gene therapies for rare paediatric diseases, including neurological conditions. While Orchard operates in a different therapeutic modality (gene therapy vs. reformulated small molecules), both companies target severe paediatric conditions with limited treatment options and pursue regulatory pathways specifically designed for paediatric populations.

TypeDirect peer
Description

ADVANZ PHARMA is a specialty pharmaceutical company focused on niche and differentiated medicines for complex diseases, including hospital and specialty pharmaceuticals across Europe. Their model of licensing, developing, and commercializing specialty medicines in European and international markets directly parallels Proveca's paediatric pharmaceutical strategy.

TypeDirect peer
Description

Norgine is a European specialty pharmaceutical company that develops, licenses, and commercializes innovative medicines across various therapeutic areas, including gastroenterology and other specialties. Norgine's European commercial infrastructure and specialty pharma licensing model closely resembles Proveca's distribution and licensing approach.

TypeBroad incumbent
Description

Mallinckrodt is a specialty pharmaceutical company that develops and commercializes medicines across multiple therapeutic areas including neurology and cardiology, with paediatric formulations in their portfolio. While significantly larger than Proveca, Mallinckrodt represents a broader incumbent with overlapping therapeutic focus areas.

TypeBroad incumbent
Description

Aspen Pharmacare is a global specialty and generic pharmaceutical company with significant presence in emerging markets and a paediatric pharmaceutical portfolio. Aspen's model of distributing specialty and generic medicines across multiple geographies, including emerging markets, provides a comparable distribution and licensing pattern to Proveca's international expansion.

TypeDirect peer
Description

Clinigen Group is a UK-based specialty pharmaceutical company that provides access to medicines through licensing, distribution, and clinical trial supply services. Clinigen's model of managing medicine access across multiple geographies and therapeutic areas closely parallels Proveca's distribution and licensing infrastructure approach.

TypeEmerging player
Description

Theravance Biopharma is a specialty pharmaceutical company focused on developing and commercializing medicines for serious diseases, including respiratory and gastrointestinal conditions. While operating at a different scale and therapeutic focus, Theravance represents a comparable specialty pharma model of developing differentiated medicines for specific patient populations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proveca

Pediatric Pharmaceuticalsproveca.com

Proveca is a UK-based specialty pharmaceutical company founded in 2010 that develops and licenses age-appropriate medicines for children, focusing on paediatric neurology and cardiology through the EMA PUMA regulatory pathway across Europe and select international markets.

What Proveca does

Proveca is a UK-based specialty pharmaceutical company founded in 2010 by Simon Bryson and Helen Shaw, exclusively focused on developing and licensing age-appropriate medicines for children. The company addresses the systemic problem that approximately half of medicines administered to children are in the wrong format or unlicensed for paediatric use, leading to safety and adherence risks. Proveca targets two therapeutic areas — neurology (chronic neurological disorders including cerebral palsy and epilepsy-related sialorrhoea) and cardiology (paediatric heart failure, hypertension, and oedema) — where approximately 80% of children with heart failure currently receive off-label adult medications. The company has contributed to 5 of the 10 PUMAs ever granted globally.

The core technology centres on proprietary orodispersible tablet formulations designed specifically for paediatric administration, including 2mm mini-tablets (Aqumeldi) and score-line tablets enabling accurate 2.5mg dosing (Bopediat). Three core products are Sialanar® (glycopyrronium bromide) for severe sialorrhea in children with chronic neurological disorders, Aqumeldi® (enalapril maleate) for paediatric heart failure, and Bopediat® (furosemide) pending European Commission approval. The pipeline includes Captopril, additional Enalapril and Furosemide protocols.

The business model is licensing-based commercialisation through the EMA PUMA pathway. Proveca generates revenue from product sales across direct sales channels in the EU and UK, plus distribution partnerships internationally (Tamro/Oriola for Nordics, Eurocept for Netherlands, BCWorld Healthcare for South Korea, and regional distributors in Eastern Europe and Latin America). Customer segments are paediatric healthcare providers (hospitals, paediatricians, neurologists, cardiologists), with end beneficiaries being children from birth to under 18 years. The company is venture capital-backed by AlbionVC and Catapult Ventures, operates through wholly-owned subsidiaries in the UK, Ireland, Germany, Italy, and France, and is pursuing US market entry via an FDA NDA for Aqumeldi submitted in March 2026.

Proveca firmographics

Firmographics
Name
Proveca
Legal name
Proveca Ltd
Website
https://proveca.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Proveca is a UK-based specialty pharmaceutical company founded in 2010 that develops and licenses age-appropriate medicines for children, focusing on paediatric neurology and cardiology through the EMA PUMA regulatory pathway across Europe and select international markets.
Ownership category
akta.pro rank

Proveca industry classification

Industry
Product category
Pediatric Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAJADAI
Regulatory Affairs, Labeling & Advertising/Promotion Compliance
Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

Keywords

  • Pediatric pharmaceuticals
  • Age-appropriate formulations
  • Orodispersible tablets
  • Paediatric neurology medicines
  • Paediatric cardiology medicines

Where Proveca is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Proveca business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

  1. Product sales - Sialanar: Proveca generates revenue from commercialising licensed paediatric medicines. Sialanar® (glycopyrronium bromide) is marketed for neurological conditions including chronic drooling in children with neurological disorders.
  2. Product sales - Aqumeldi: Aqumeldi® (enalapril maleate) is commercialised for paediatric heart failure in Europe and UK, with NDA submitted to FDA for US market expansion.
  3. Product sales - Bopediat: Bopediat® (furosemide) orodispersible tablets received positive EMA opinion for PUMA, pending European Commission approval for treatment of oedema and hypertension in children.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Proveca product offering

Product offering

Core offering

Proveca is a global pharmaceutical company that develops and licenses age-appropriate medicines for children in neurology and cardiology therapy areas. The company identifies off-patent medicines with unmet paediatric healthcare needs and obtains Paediatric Use Marketing Authorisations (PUMA) and other marketing authorisations to bring licensed paediatric formulations such as Sialanar® (glycopyrronium bromide), Aqumeldi® (enalapril maleate), and Bopediat® (furosemide) to market.

Product overview

Proveca is a pharmaceutical company specialising in the development and licensing of medicines for children. The company focuses on identifying off-patent medicines with unmet priority healthcare needs in the paediatric market, obtaining paediatric licences through the PUMA (Paediatric Use Marketing Authorisation) pathway and national marketing authorisations. Current approved products include Sialanar® (glycopyrronium bromide) for neurological conditions causing chronic drooling/sialorrhea, and Aqumeldi® (enalapril maleate) for cardiology conditions. Bopediat® (furosemide) is pending European Commission approval. The product portfolio spans neurology and cardiology therapy areas, with medicines designed in age-appropriate formats such as orodispersible tablets.

Differentiator

Problem solved

Functional benefit

Brands

  • Bopediat®: Furosemide orodispersible tablets for treatment of oedema and hypertension in children from birth to less than 18 years
  • Sialanar®
  • Aqumeldi®

Products and services

  • Sialanar® Glycopyrronium bromide 400mcg/ml oral solution indicated for symptomatic treatment of severe sialorrhea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Licensed via PUMA and launched across multiple European markets, South Korea, and South America.
  • Aqumeldi® Enalapril maleate orodispersible mini tablet (0.25mg and 1mg) indicated for treatment of heart failure in children from birth to less than 18 years, and for treatment of hypertension. Licensed for paediatric heart failure in Europe and UK, with NDA submitted to FDA for US market expansion.
  • Bopediat® Furosemide 5mg orodispersible tablet with functional score line enabling accurate 2.5mg doses. Indicated in children from birth to less than 18 years for treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease. Awaiting European Commission approval.

Quantifiable outcome

  • 80% of children with heart failure currently receive off-label adult medications
  • +2 more outcomes

Companies that use Proveca

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Proveca technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Proveca partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and supporting.

  • BCWorld HealthcarecoreChannel Partner/ Reseller/ Distributor · 1 March 2024In March 2024, Proveca entered into a partnership agreement with BCWorld Healthcare, granting exclusive rights for licensing and distribution of Sialanar® in South Korea. BCWorld submitted NDA in October 2024 and received marketing authorisation from MFDS in August 2025. The product launched in South Korea in March 2026 for treatment of severe sialorrhea in children aged 3 years and older with chronic neurological disorders.
  • Aston UniversitysupportingStrategic or Co-development Partner · 29 November 2022Proveca partnered with Aston University to support final research projects for MSc Pharmaceutical Sciences, Drug Delivery and MPharm students. The partnership includes PhD sponsorship, research supervision, workshops on drug formulation challenges, and student project support. Joint work explores development of drug formulations.
  • Alder Hey Children's HospitalcoreStrategic or Co-development Partner · 5 January 2022Collaboration between Alder Hey Children's Hospital and Proveca Ltd to improve children's medicines. The partnership aims to provide the best pharmaceutical treatments for children by identifying existing gaps and developing new products specifically for children and young people. Alder Hey brings expertise in paediatric healthcare and their NIHR-funded Clinical Research Facility.
  • Tamro ABsupportingChannel Partner/ Reseller/ DistributorTamro AB manages distribution of Proveca medicines to Norway, Sweden, Denmark, and Iceland, supplying these countries via local wholesalers.
  • Oriola ABsupportingChannel Partner/ Reseller/ DistributorOriola AB is responsible for Proveca Pharma Ltd's regulatory, quality, and pharmacovigilance obligations in the Nordic region.
  • Eurocept PharmaceuticalssupportingChannel Partner/ Reseller/ DistributorEurocept Pharmaceuticals handles adverse event reporting and product distribution for Sialanar® and Aqumeldi® products in the Netherlands.
  • European Medicines Agency (EMA)coreOthersProveca works with EMA for regulatory approvals through the Paediatric Use Marketing Authorisation (PUMA) pathway. EMA CHMP adopted positive opinion for Bopediat® in March 2026.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Proveca competitors and assessment

Company assessment

Direct peers

  • Swedish Orphan Biovitrum (Sobi): Swedish Orphan Biovitrum is a European specialty pharmaceutical company focused on rare diseases and specialty medicines, including paediatric indications. Sobi's commercial model of licensing, developing, and distributing niche specialty medicines across global markets closely parallels Proveca's paediatric pharmaceutical strategy, though Sobi operates at significantly larger scale.
  • ADVANZ PHARMA (formerly Concordia International): ADVANZ PHARMA is a specialty pharmaceutical company focused on niche and differentiated medicines for complex diseases, including hospital and specialty pharmaceuticals across Europe. Their model of licensing, developing, and commercializing specialty medicines in European and international markets directly parallels Proveca's paediatric pharmaceutical strategy.
  • Norgine: Norgine is a European specialty pharmaceutical company that develops, licenses, and commercializes innovative medicines across various therapeutic areas, including gastroenterology and other specialties. Norgine's European commercial infrastructure and specialty pharma licensing model closely resembles Proveca's distribution and licensing approach.
  • Clinigen Group: Clinigen Group is a UK-based specialty pharmaceutical company that provides access to medicines through licensing, distribution, and clinical trial supply services. Clinigen's model of managing medicine access across multiple geographies and therapeutic areas closely parallels Proveca's distribution and licensing infrastructure approach.

Broad incumbents

  • Jazz Pharmaceuticals: Jazz Pharmaceuticals acquired GW Pharmaceuticals, which developed cannabinoid-based paediatric epilepsy treatments, demonstrating a similar specialty pharma model of developing differentiated paediatric formulations for neurological conditions. Jazz represents a broader incumbent player with paediatric neurology exposure and significant commercial scale.
  • BioMarin Pharmaceutical: BioMarin is a specialty biopharmaceutical company focused on rare diseases, with several paediatric products across multiple therapeutic areas including neurology and cardiology. BioMarin's paediatric rare disease franchise, combined with global commercial infrastructure, makes it a comparable incumbent peer in paediatric specialty pharma, though at substantially larger scale.
  • Mallinckrodt Pharmaceuticals: Mallinckrodt is a specialty pharmaceutical company that develops and commercializes medicines across multiple therapeutic areas including neurology and cardiology, with paediatric formulations in their portfolio. While significantly larger than Proveca, Mallinckrodt represents a broader incumbent with overlapping therapeutic focus areas.
  • Aspen Pharmacare: Aspen Pharmacare is a global specialty and generic pharmaceutical company with significant presence in emerging markets and a paediatric pharmaceutical portfolio. Aspen's model of distributing specialty and generic medicines across multiple geographies, including emerging markets, provides a comparable distribution and licensing pattern to Proveca's international expansion.

Emerging players

  • Orchard Therapeutics: Orchard Therapeutics is a biotechnology company developing gene therapies for rare paediatric diseases, including neurological conditions. While Orchard operates in a different therapeutic modality (gene therapy vs. reformulated small molecules), both companies target severe paediatric conditions with limited treatment options and pursue regulatory pathways specifically designed for paediatric populations.
  • Theravance Biopharma: Theravance Biopharma is a specialty pharmaceutical company focused on developing and commercializing medicines for serious diseases, including respiratory and gastrointestinal conditions. While operating at a different scale and therapeutic focus, Theravance represents a comparable specialty pharma model of developing differentiated medicines for specific patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Proveca social profiles

Digital presence

Proveca financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proveca leadership team

Management profile

Number of profiles

Profiles6 records

Proveca subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Proveca funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proveca M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proveca

What does Proveca do?

Proveca is a global pharmaceutical company that develops and licenses age-appropriate medicines for children in neurology and cardiology therapy areas. The company identifies off-patent medicines with unmet paediatric healthcare needs and obtains Paediatric Use Marketing Authorisations (PUMA) and other marketing authorisations to bring licensed paediatric formulations such as Sialanar® (glycopyrronium bromide), Aqumeldi® (enalapril maleate), and Bopediat® (furosemide) to market.

Is Proveca a public or private company?

Proveca is a private company. It is classified as venture growth investor backed and is currently operating.

When was Proveca founded?

Proveca was founded in 2010. It employs 51 to 100 people.

Where is Proveca based?

Proveca is headquartered in Manchester, United Kingdom, in the Europe region.

How does Proveca make money?

Three revenue lines are on record. Product sales - Sialanar is the primary driver. The others are product sales - Aqumeldi and product sales - Bopediat.

Who are Proveca's main competitors?

Direct peers on record are Swedish Orphan Biovitrum (Sobi), ADVANZ PHARMA (formerly Concordia International), Norgine and Clinigen Group. Broad incumbents are Jazz Pharmaceuticals, BioMarin Pharmaceutical, Mallinckrodt Pharmaceuticals and Aspen Pharmacare. Emerging players are Orchard Therapeutics and Theravance Biopharma.

Does Proveca have an API?

No public API is recorded for Proveca.

What industry is Proveca in?

Proveca's product category is Pediatric Pharmaceuticals. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAJADAI, Regulatory Affairs, Labeling & Advertising/Promotion Compliance. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comProveca and Cessatech plan next regulatory steps for KemSu following CHMP opinionThe EMA's CHMP maintained its negative opinion on the PUMA application for KemSu, a ketamine/sufentanil nasal spray for children's acute pain. Proveca and Cessatech will seek scientific advice to address remaining gaps and define a regulatory pathway for resubmission. The companies remain committed to making KemSu available to children needing new treatment options.news.cision.comProveca intends to request a re-examination of CHMP opinion for CT001/KemSuThe EMA's CHMP adopted a negative opinion on Proveca's PUMA application for CT001/KemSu, a ketamine/sufentanil nasal spray for children's acute pain. Proveca plans to request a re-examination of the opinion, with the process expected to take several months.PR NewswireCessatech and Proveca announce world-wide excluding US commercial partnership for CT001Cessatech and Proveca signed an exclusive agreement to commercialize CT001 worldwide excluding the US, with Proveca as marketing authorization holder. The deal includes an upfront payment and double-digit royalties, and Proveca also received a non-exclusive option to license CT002.PR NewswireGlobal Sialorrhea Market Report 2017-2028: Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, Current & Forecasted Market SizeResearchAndMarkets released a market report on the sialorrhea (excessive drooling) treatment market covering seven major markets (US, EU5, Japan), valued at USD 1,073.62 million in 2017 and projected to grow through 2028. The report analyzes current treatment practices, pipeline drugs including anticholinergics and botulinum toxins, and market share of individual therapies across major pharmaceutical companies. Key marketed products include Merz Pharmaceuticals' Cuvposa and Proveca Pharma's Sialanar, while emerging therapies include US WorldMeds' Myobloc, Merz Pharma's Xeomin, and NeuroHealing's NH004.FinSMEsProveca Raises £4M in FundingProveca, a Manchester-based pharmaceutical company, raised £4M in funding led by Catapult Ventures with growth debt from Kreos Capital. The company will use the funds for the commercial roll-out of Sialanar, a treatment for chronic pathological drooling in children.